AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
New study: Pharmacogenomic tests have key applications in cancer and infectious disease.
2002 AUG 8 - (NewsRx.com & NewsRx.net) -- "Predictive Pharmacogenomics: Revolutionizing Health Care," published by Cambridge Healthtech Institute (CHI), examines developing technologies designed to use an individual's genomic profile to predict response to certain drugs, enabling better treatment decisions and safer medical care.
Pharmacogenomic tests are already being used to predict patient response to therapy in the fields of cancer and infectious disease; these two important applications are discussed in detail in this report.
The most notable example in the cancer arena is the testing of breast cancer patients for the presence of estrogen and progesterone receptors in their tumors to predict whether they are likely to respond to hormonal therapy. Breast cancer patients are also tested for overexpression of HER-2/neu before they are given Genentech's Herceptin (trastuzumab), since only those patients whose tumors overexpress HER-2/neu will respond to this therapy.
The fields of antiviral, antibacterial, and antifungal therapy are faced with a different issue - the growing problem of microbial drug resistance, and the need to be able to predict which antimicrobial agents are likely to be effective in treating specific infections. Viral resistance is a major problem in treating HIV infection. Both types of HIV drug-resistance assays-genotyping assays and phenotyping ...
- Pharmacogenomic Tests Have Important Applications in Cancer and Infectious...
- Press release article from: PR Newswire June 24, 2002 700+ words
...and safer medical care. Pharmacogenomic tests are already being used to...infection. Both types of HIV drug-resistance assays-genotyping...potential clinical usefulness of HIV drug- resistance testing. The...companies have developed HIV drug-resistance tests. The...
- Celera and Ipsen Enter Research Collaboration to Develop Pharmacogenomic Tests.
- Press release article from: Business Wire November 20, 2007 700+ words
...FR0010259150;IPN) today announced that they have entered into a research collaboration to develop biomarker and pharmacogenomic tests for growth failure patients. The initial phase of the collaboration will focus on the discovery and characterization...
- Celera Enters Oncology Research Collaboration with Merck to Develop...
- Press release article from: Business Wire September 17, 2007 700+ words
...business, has entered into a research collaboration with Merck & Co., Inc., to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate the use of certain gene expression...
- Ipsen SA, of Paris, and Celera Group, of Alameda, Calif., formed a research...
- Newspaper article from: BioWorld International November 28, 2007 700+ words
...Paris, and Celera Group, of Alameda, Calif., formed a research collaboration to develop biomarker and pharmacogenomic tests for growth failure. Celera will receive an undisclosed payment for the initial phase of the collaboration...
- Celera (Rockville, Maryland), an Applera (Norwalk, Connecticut) business, said...
- Newspaper article from: Diagnostics & Imaging Week September 20, 2007 700+ words
...entered into a research collaboration with Merck (Whitehouse Station, New Jersey) to develop biomarker and pharmacogenomic tests for cancer patients. Celera will evaluate the use of certain gene expression profiles identified by Merck with...
- BIOTECHNOLOGY NEWSWATCH: Pharmacogenomic tests focus on collaboration.
- News wire article from: Chemical Business Newsbase August 27, 2001 700+ words
DeCODE Genetics (Reykyavik, Iceland) and Affymetrix (Santa Clara, CA) have entered into a collaboration to develop tests aimed at tailoring drug therapy to individuals. The companies will initially study gene expression to uncover how bodies react to medicines. The clinical work will be carried out
- Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic...
- Press release article from: Business Wire October 23, 2007 700+ words
AUSTIN, Texas -- Asuragen Pharmacogenomic Services, a division of Asuragen, Inc. (Austin, Texas), has entered into a research collaboration with Merck & Co., Inc. to develop a biomarker and pharmacogenomic test for cancer clinical trials. Under the terms of the agreement, Asuragen will apply
- Samaritan Pharmaceuticals Advances HIV Drug Pipeline: Files Three New HIV...
- Press release article from: Business Wire May 6, 2004 700+ words
...Second Generation HIV Drugs, Effective for HIV Drug Resistance as Entry Inhibitor Drug -- New...announces it is encouraged by the progress of its HIV drug candidate SP-01A. Samaritan's HIV drug SP-01A completed FDA Phase Ib/Phase IIa...
- ViroLogic Announces Availability of Novel, Rapid HIV Drug Resistance Test,...
- Press release article from: Business Wire June 23, 1999 700+ words
...Phenotypic Test Is Designed To Help Guide HIV Drug Therapy, Reduce Treatment Costs And Improve...HIV, the company's rapid phenotypic HIV drug resistance assay. In a time of rising HIV drug resistance and increasing treatment choices...
- ViroLogic Announces Availability of Novel, Rapid HIV Drug Resistance Test,...
- Press release article from: PR Newswire June 23, 1999 700+ words
...Phenotypic Test is Designed to Help Guide HIV Drug Therapy, Reduce Treatment Costs and Improve...HIV, the company's rapid phenotypic HIV drug resistance assay. In a time of rising HIV drug resistance and increasing treatment choices...
Source: HighBeam Research, New study: Pharmacogenomic tests have key applications in cancer and...